MX2013013307A - Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. - Google Patents

Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.

Info

Publication number
MX2013013307A
MX2013013307A MX2013013307A MX2013013307A MX2013013307A MX 2013013307 A MX2013013307 A MX 2013013307A MX 2013013307 A MX2013013307 A MX 2013013307A MX 2013013307 A MX2013013307 A MX 2013013307A MX 2013013307 A MX2013013307 A MX 2013013307A
Authority
MX
Mexico
Prior art keywords
lixisenatide
metformin
diabetes type
treatment
combination
Prior art date
Application number
MX2013013307A
Other languages
English (en)
Other versions
MX362527B (es
Inventor
Louise Silvestre
Patrick Miossec
Peter Ruus
Jean-Louis Pinquier
Agnes Hincelin-Mery
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46148833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013013307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MX2013013307A publication Critical patent/MX2013013307A/es
Publication of MX362527B publication Critical patent/MX362527B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica para uso en el control glucémico en pacientes con diabetes de tipo 2.
MX2013013307A 2011-05-13 2012-05-11 Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. MX362527B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166120 2011-05-13
EP12163637 2012-04-10
PCT/EP2012/058747 WO2012156298A1 (en) 2011-05-13 2012-05-11 Lixisenatide and metformin for treatment of diabetes type 2

Publications (2)

Publication Number Publication Date
MX2013013307A true MX2013013307A (es) 2014-03-12
MX362527B MX362527B (es) 2019-01-23

Family

ID=46148833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013307A MX362527B (es) 2011-05-13 2012-05-11 Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.

Country Status (19)

Country Link
US (1) US20130065828A1 (es)
EP (1) EP2707017B1 (es)
JP (2) JP6442284B2 (es)
KR (1) KR20140043755A (es)
CN (2) CN103841988A (es)
AU (1) AU2012257849B2 (es)
BR (1) BR112013029062A2 (es)
CA (1) CA2835259C (es)
CY (1) CY1117250T1 (es)
DK (1) DK2707017T3 (es)
ES (1) ES2556466T3 (es)
HR (1) HRP20151369T1 (es)
HU (1) HUE028459T2 (es)
MX (1) MX362527B (es)
PL (1) PL2707017T3 (es)
PT (1) PT2707017E (es)
RU (1) RU2623023C2 (es)
SI (1) SI2707017T1 (es)
WO (1) WO2012156298A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
CA2932873A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
AR103415A1 (es) * 2015-01-16 2017-05-10 Sanofi Aventis Deutschland Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AU2019309798A1 (en) 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
US12465016B2 (en) 2019-12-19 2025-11-11 Allflex USA LLC Vaccination identification button for electronic identification button tags to identify cattle as being inoculated against brucellosis, and kits and methods related thereto
TW202228762A (zh) 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
CN101291685A (zh) * 2005-08-19 2008-10-22 安米林药品公司 治疗糖尿病和降低体重的毒蜥外泌肽
JP5399244B2 (ja) * 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
WO2010092163A2 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
SI2324853T1 (sl) 2009-11-13 2015-12-31 Sanofi-Aventis Deutschland Gmbh Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2

Also Published As

Publication number Publication date
HRP20151369T1 (hr) 2016-01-15
WO2012156298A1 (en) 2012-11-22
RU2623023C2 (ru) 2017-06-21
AU2012257849B2 (en) 2017-03-30
JP6676108B2 (ja) 2020-04-08
CA2835259A1 (en) 2012-11-22
ES2556466T3 (es) 2016-01-18
US20130065828A1 (en) 2013-03-14
MX362527B (es) 2019-01-23
HUE028459T2 (en) 2016-12-28
DK2707017T3 (en) 2016-01-04
JP2018184441A (ja) 2018-11-22
JP2014514356A (ja) 2014-06-19
SI2707017T1 (sl) 2016-01-29
BR112013029062A2 (pt) 2016-11-29
CN103841988A (zh) 2014-06-04
CY1117250T1 (el) 2017-04-05
JP6442284B2 (ja) 2018-12-19
KR20140043755A (ko) 2014-04-10
HK1194307A1 (en) 2014-10-17
RU2013155474A (ru) 2015-06-20
EP2707017B1 (en) 2015-09-16
CN107693782A (zh) 2018-02-16
PL2707017T3 (pl) 2016-03-31
PT2707017E (pt) 2016-01-12
CA2835259C (en) 2020-01-07
EP2707017A1 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
MX362527B (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
MX362503B (es) Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal.
MX2014002159A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
EA201101037A1 (ru) Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MX2015008079A (es) Agonista duales de glp1/gip o trigonales de glp1/gip/glucagon.
PH12012502121A1 (en) Peptide conjugates of glp-1 receptor agonists and gastrin and their use
IN2014CN02616A (es)
MX2014015423A (es) Analogos de peptido de exedina-4.
PH12016500606A1 (en) Insulin preparations containing methionine
MX2015016715A (es) Agonistas del receptor de la vitamina d para tratar enfermedades que afectan a la actividad de cxcl12.
MX2014005351A (es) Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
PH12017501662A1 (en) Treatment type 2 diabetes mellitus patients
MX366685B (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.

Legal Events

Date Code Title Description
FG Grant or registration